# Dose-escalation, and Safety Study of LDE225 and Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer Patients

> **NCT01487785** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 18 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** LDE225+gemcitabine

## Key facts

- **NCT ID:** NCT01487785
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-03
- **Primary completion:** 2014-07
- **Final completion:** 2014-07
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2020-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01487785

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01487785, "Dose-escalation, and Safety Study of LDE225 and Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01487785. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*